Heinz‐Josef Lenz

University of North Carolina at Chapel Hill — United States

Medicine · Health Sciences

106h-index56.2kcitations1.9kworks4.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(963), Genetic factors in colorectal cancer(378), Cancer Genomics and Diagnostics(319), Gastric Cancer Management and Outcomes(286), Cancer Treatment and Pharmacology(258)

Publications1.8k total

Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy
UNC Libraries·2025Open Access
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance)
UNC Libraries·2025Open Access
CheckMate 8HW and the future of dual immunotherapy – Authors' reply
The Lancet·2025Open Access
Genome‐wide association studies of survival in 1520 cancer patients treated with bevacizumab‐containing regimens
UNC Libraries·2025Open Access
Table 2 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Table 1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025· 1 citedOpen Access
Supplementary Table S2 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Table 3 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Data from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Supplementary Table S4 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer
Nature Communications·2025· 1 citedOpen Access
Figure 1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Supplementary Table S1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Supplementary Table S3 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Supplementary Table S5 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Figure 2 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Table 4 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Abstract A158: Experiences and preliminary results of a community-based randomized controlled trial to raise colorectal cancer awareness: Findings from the Community Genetic Navigation Engagement Specialist (CoGENES) program
Cancer Epidemiology Biomarkers & Prevention·2025
Abstract A039: Colorectal cancer in Hispanic and Latino populations: Genetic similarity and molecular drivers identified via multi-omics analysis
Cancer Epidemiology Biomarkers & Prevention·2025
A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
Cancer Research Communications·2025Open Access
page 1 of 92Next →

Frequent Co-authors

Eric Van Cutsem(9), Richard M. Goldberg(9), Howard S. Höchster(8), Josep Tabernero(7), Robert J. Mayer(7), Alan P. Venook(7), Donna Niedzwiecki(6), Federico Innocenti(6), Charles D. Blanke(6), Alfredo Falcone(5), Wu Zhang(5), Monica M. Bertagnolli(5), Susan Groshen(5), Alberto Sobrero(4), Takayuki Yoshino(4), Thierry André(4), Scott Kopetz(4), James N. Atkins(4), Blasé N. Polite(4), Dongyun Yang(4)